A clinical case report published by researchers at the Universitat Autònoma de Barcelona (UAB) has documented what the authors describe as the first reported instance of neonatal abstinence syndrome (NAS) attributable to heavy maternal consumption of yerba mate during pregnancy. The case adds a novel entry to the medical literature on caffeine-related neonatal withdrawal — a phenomenon previously documented only in the context of high coffee or energy drink intake.
The Clinical Presentation
The case involved a premature infant whose mother reported consuming large quantities of yerba mate throughout pregnancy. After delivery, the neonate exhibited a cluster of neurological symptoms consistent with NAS: increased jitteriness, marked irritability, a characteristic high-pitched cry, and other mild neurological abnormalities. The symptom profile prompted clinicians to investigate potential substance exposures beyond conventional drugs of abuse.
Analysis of maternal and neonatal biological samples revealed elevated concentrations of both caffeine and theobromine — two methylxanthine alkaloids that are abundantly present in Ilex paraguariensis. The dual-compound finding is notable because it distinguishes yerba mate exposure from coffee exposure: while coffee is dominated by caffeine alone, yerba mate delivers significant amounts of both caffeine (approximately 78 mg per 150 mL serving) and theobromine (approximately 19 mg per serving), indicating chronic, heavy exposure to a broader methylxanthine cocktail.
Methylxanthines and Fetal Exposure
Methylxanthines cross the placental barrier freely, and fetal metabolism of these compounds is substantially slower than in adults due to immature hepatic enzyme systems — particularly cytochrome P450 1A2 (CYP1A2), which is the primary pathway for caffeine clearance. Premature neonates are especially vulnerable because their already-limited metabolic capacity is further reduced. The resulting accumulation can produce central nervous system stimulation and, upon cessation of exposure at birth, a withdrawal syndrome indistinguishable from that caused by other psychoactive substances.
Clinical Implications and Context
The UAB authors emphasize that the case does not constitute grounds for broad prohibitions on yerba mate consumption during pregnancy, but rather highlights the importance of quantifying total daily methylxanthine intake from all sources — including tea, coffee, chocolate, and mate — when counseling pregnant patients. Current World Health Organization guidelines recommend limiting caffeine intake to below 200–300 mg per day during pregnancy, a threshold that can be reached with as few as three to four servings of traditionally prepared mate.
The report has drawn attention from neonatologists and toxicologists for its methodological clarity: the researchers systematically excluded other potential causes of NAS through comprehensive toxicology screening before attributing the syndrome to methylxanthine exposure. This diagnostic rigor strengthens the causal inference significantly, though the authors acknowledge that a single case report cannot establish population-level risk and call for prospective epidemiological studies in regions where yerba mate consumption during pregnancy is culturally normative.